Physician profile

Rosa A Torres

Family Medicine · Burkburnett, TX

NPI 1215032172

$1,400.41

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$390.12

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novo Nordisk INC $424.50 2019-2022
Amgen INC. $239.99 2021
Abbvie INC. $216.86 2021-2023 Ubrelvy
Astrazeneca Pharmaceuticals Lp $201.15 2024 Breztri, Farxiga
Amarin Pharma, INC. $99.09 2019
Lundbeck LLC $95.85 2023 Vyepti
Abbott Laboratories $48.77 2023 Cardiomems
Bayer Healthcare Pharmaceuticals INC. $32.23 2022
Merck Sharp & Dohme LLC $25.59 2019
Philips North America LLC $16.38 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Rosa A Torres

$1,400.41

in general payments reported 2019-2025

Years
2019-2024
Top company
Novo Nordisk INC

https://glasscript.com/doctor/54539/rosa-a-torres

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.